Artificial Intelligence

Authenticx CEO Amy Brown on why patient support AI needs continuous oversight, not just adoption.

AI-native operating systems present new capabilities to improve pharma supply chain operations.

Alexis Cogswell of Inizio Medical explains how combining real-world data, AI analysis and HCP context is helping medical affairs teams move from retrospective reporting to actionable, real-time strategy.

As pharmaceutical companies scale their use of AI across drug safety operations, the Council for International Organizations of Medical Sciences Working Group XIV's now-published guidance sets the bar for what will be required for sustained system validation.

AI-enabled pharmacovigilance is becoming a commercial capability that protects product value and speeds evidence-based market access decisions.

Ed Schoonveld examines how AI is reshaping drug pricing and access, from payer decisions to prescribing, and what it means for new drug treatments.

Pharma hub services are evolving as manufacturers navigate specialty therapy growth, digital transformation, vendor transitions, and new models for patient access and support.

Kenco has put DeepFabric's AI agents into live production across its 3PL operations, with plans to scale to 20 agents within a year.

Access leaders are pressed to prove AI ROI, but ConnectiveRx execs Cindy Baksh and Steve Randall argue the real work is defining "better" first, then deciding where AI fits.

Peli BioThermal and PAXAFE are partnering to pair cold chain packaging with AI-powered monitoring, signaling where pharma logistics technology is headed next.

Ramarketing CEO Emma Banks revisits her "year of two halves" outlook, discussing whether 2026 has followed the same pattern and what she expects for H2.

Doceree launched Semmelweis, an AI model built for pharma commercialization, as drugmakers ramp up AI investment in marketing and sales operations.

Generating real-world evidence isn't enough. What drives market access is whether payers can actually evaluate and act on it.

4flow's Natalia Andreyeva breaks down the persistent planning failures driving AI adoption in pharma supply chains.

The US DSCSA requires digital drug traceability to ensure patient safety, but supply chains face data errors; deploying AI adds an intelligent compliance layer to automate process tracking and protect drug access.

BMS will deploy enterprise AI across functions to streamline workflows, structure field insights, and improve HCP engagement and execution.

Ben Sharples, LogiPharma event director, examines how life sciences organizations are adapting to AI in the supply chain, with expert testimony from LogiPharma partners.

Joydeep Ganguly evaluates 4IR tools, data strategy, and why end-to-end thinking will define pharma supply chain transformation.

Rahul Shah and Mack MacKenzie explain how to unlock the ROI that rules-based systems have left on the table.

Brightseed debuts a clinically validated AI platform to integrate life sciences innovation from discovery to commercialization

The AI-native operating system targets complex workflows, automating claims and communications to reclaim logistics teams' time.

By unifying data, workflows, and decision-making across partners, AI orchestration is enabling healthcare supply chains to move from reactive firefighting to proactive resilience—supporting faster responses, smarter tradeoffs, and more reliable patient care delivery.

In the first part of his Pharma Commerce video interview, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, discusses how from GLP-1 adoption to specialty drugs, behavioral health utilization, and hospital consolidation, multiple forces are reshaping employer-sponsored healthcare costs—and pushing premiums and cost-sharing higher.

Traditional market access practices are being transformed by an increasingly rocky landscape of rebate, discount, and direct-distribution practices, but artificial intelligence may clear the pathways to profitability.

As safety data grows in scale and complexity, AI-powered pharmacovigilance is emerging as a strategic imperative—helping drugmakers improve detection, reduce risk, and strengthen commercial performance.